Everolimus and Sunitinib potentially work as therapeutic drugs for infantile hemangiomas.

ABSTRACT:

Background

Infantile hemangiomas (IH) are common vascular tumors in infants, with no well-defined therapeutic agents currently available. Recent studies have explored molecular mechanisms involved in IH progression, but the lack of immortalized hemangioma-derived endothelial cell (iHemEC) models has limited drug discovery efforts.

Methods

We established an immortalized hemangioma-derived endothelial cell (iHemEC) expressing hemangioma markers and screened 18 potential drugs. Transcriptome profiling and Gene Set Enrichment Analysis (GSEA) were applied to assess the molecular effects of Everolimus and Sunitinib.

Results

Sunitinib, Elimusertib, HIF-1 inhibitor-4, Rebastinib, and Everolimus inhibited iHemEC with lower IC₅₀ than Propranolol and Rapamycin. GSEA s

SUBMITTER: Xie R 

PROVIDER: S-EPMC12811115 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature